These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17544282)

  • 1. Pyrrolidinones as orally bioavailable antagonists of the human melanocortin-4 receptor with anti-cachectic activity.
    Tran JA; Tucci FC; Jiang W; Marinkovic D; Chen CW; Arellano M; Markison S; Fleck BA; Wen J; White NS; Pontillo J; Saunders J; Marks D; Hoare SR; Madan A; Foster AC; Chen C
    Bioorg Med Chem; 2007 Aug; 15(15):5166-76. PubMed ID: 17544282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor.
    Jiang W; Tucci FC; Tran JA; Fleck BA; Wen J; Markison S; Marinkovic D; Chen CW; Arellano M; Hoare SR; Johns M; Foster AC; Saunders J; Chen C
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5610-3. PubMed ID: 17822895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists.
    Chen C; Tucci FC; Jiang W; Tran JA; Fleck BA; Hoare SR; Wen J; Chen T; Johns M; Markison S; Foster AC; Marinkovic D; Chen CW; Arellano M; Harman J; Saunders J; Bozigian H; Marks D
    Bioorg Med Chem; 2008 May; 16(10):5606-18. PubMed ID: 18417348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent and orally active non-peptide antagonists of the human melanocortin-4 receptor based on a series of trans-2-disubstituted cyclohexylpiperazines.
    Tucci FC; White NS; Markison S; Joppa M; Tran JA; Fleck BA; Madan A; Dyck BP; Parker J; Pontillo J; Arellano LM; Marinkovic D; Jiang W; Chen CW; Gogas KR; Goodfellow VS; Saunders J; Foster AC; Chen C
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4389-95. PubMed ID: 16098742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.
    Chen C; Jiang W; Tucci F; Tran JA; Fleck BA; Hoare SR; Joppa M; Markison S; Wen J; Sai Y; Johns M; Madan A; Chen T; Chen CW; Marinkovic D; Arellano M; Saunders J; Foster AC
    J Med Chem; 2007 Nov; 50(22):5249-52. PubMed ID: 17918824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor.
    Tran JA; Jiang W; Tucci FC; Fleck BA; Wen J; Sai Y; Madan A; Chen TK; Markison S; Foster AC; Hoare SR; Marks D; Harman J; Chen CW; Arellano M; Marinkovic D; Bozigian H; Saunders J; Chen C
    J Med Chem; 2007 Dec; 50(25):6356-66. PubMed ID: 17994683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arylpropionylpiperazines as antagonists of the human melanocortin-4 receptor.
    Jiang W; Tucci FC; Chen CW; Arellano M; Tran JA; White NS; Marinkovic D; Pontillo J; Fleck BA; Wen J; Saunders J; Madan A; Foster AC; Chen C
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4674-8. PubMed ID: 16777413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-{(2R)-[3-Aminopropionylamido]-3-(2,4-dichlorophenyl)propionyl}-1-{2-[(2-thienyl)ethylaminomethyl]phenyl}piperazine as a potent and selective melanocortin-4 receptor antagonist--design, synthesis, and characterization.
    Chen C; Pontillo J; Fleck BA; Gao Y; Wen J; Tran JA; Tucci FC; Marinkovic D; Foster AC; Saunders J
    J Med Chem; 2004 Dec; 47(27):6821-30. PubMed ID: 15615531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice.
    Nicholson JR; Kohler G; Schaerer F; Senn C; Weyermann P; Hofbauer KG
    J Pharmacol Exp Ther; 2006 May; 317(2):771-7. PubMed ID: 16436498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MC4 receptor antagonists: a potential treatment for cachexia.
    Foster AC; Chen C; Markison S; Marks DL
    IDrugs; 2005 Apr; 8(4):314-9. PubMed ID: 15800806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticatabolic properties of melanocortin-4 receptor antagonists.
    Madison LD; Marks DL
    Curr Opin Clin Nutr Metab Care; 2006 May; 9(3):196-200. PubMed ID: 16607116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist.
    Hong Q; Bakshi RK; Palucki BL; Park MK; Ye Z; He S; Pollard PG; Sebhat IK; Liu J; Guo L; Cashen DE; Martin WJ; Weinberg DH; MacNeil T; Tang R; Tamvakopoulos C; Peng Q; Miller RR; Stearns RA; Chen HY; Chen AS; Strack AM; Fong TM; MacIntyre DE; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2330-4. PubMed ID: 21439820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propionylpiperazines as human melanocortin-4 receptor ligands.
    Chen CW; Tran JA; Jiang W; Tucci FC; Arellano M; Wen J; Fleck BA; Marinkovic D; White NS; Pontillo J; Saunders J; Madan A; Foster AC; Chen C
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4800-3. PubMed ID: 16824757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and SAR of potent and orally bioavailable tert-butylpyrrolidine archetype derived melanocortin subtype-4 receptor modulators.
    Guo L; Ye Z; Ujjainwalla F; Sings HL; Sebhat IK; Huber J; Weinberg DH; Tang R; MacNeil T; Tamvakopoulos C; Peng Q; MacIntyre E; van der Ploeg LH; Goulet MT; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3242-7. PubMed ID: 18479920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease.
    DeBoer MD; Marks DL
    Nat Clin Pract Endocrinol Metab; 2006 Aug; 2(8):459-66. PubMed ID: 16932335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cachexia: lessons from melanocortin antagonism.
    Deboer MD; Marks DL
    Trends Endocrinol Metab; 2006 Jul; 17(5):199-204. PubMed ID: 16750633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of piperazinebenzylamines with a N-(1-methoxy-2-propyl) side chain as potent and selective antagonists of the human melanocortin-4 receptor.
    Pontillo J; Marinkovic D; Tran JA; Arellano M; Fleck BA; Wen J; Tucci FC; Nelson J; Saunders J; Foster AC; Chen C
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4615-8. PubMed ID: 16105734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists.
    Xin Z; Serby MD; Zhao H; Kosogof C; Szczepankiewicz BG; Liu M; Liu B; Hutchins CW; Sarris KA; Hoff ED; Falls HD; Lin CW; Ogiela CA; Collins CA; Brune ME; Bush EN; Droz BA; Fey TA; Knourek-Segel VE; Shapiro R; Jacobson PB; Beno DW; Turner TM; Sham HL; Liu G
    J Med Chem; 2006 Jul; 49(15):4459-69. PubMed ID: 16854051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piperazinebenzylamines as potent and selective antagonists of the human melanocortin-4 receptor.
    Pontillo J; Tran JA; Fleck BA; Marinkovic D; Arellano M; Tucci FC; Lanier M; Nelson J; Parker J; Saunders J; Murphy B; Foster AC; Chen C
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5605-9. PubMed ID: 15482933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of pyrrolidine diastereoisomers as potent functional agonists and antagonists of the human melanocortin-4 receptor.
    Chen C; Jiang W; Tran JA; Tucci FC; Fleck BA; Markison S; Wen J; Madan A; Hoare SR; Foster AC; Marinkovic D; Chen CW; Arellano M; Saunders J
    Bioorg Med Chem Lett; 2008 Jan; 18(1):129-36. PubMed ID: 18032040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.